{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:58:13Z","timestamp":1784872693435,"version":"3.55.0"},"reference-count":7,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,20]]},"abstract":"<jats:p>The results of this study suggest that progressive discontinuation of mogamulizumab (Moga) should be considered once a response is obtained in patients with S\u00e9zary syndrome, even after a short treatment duration. This may minimize the risk of adverse effects, costs and resistance to Moga. Additionally, our study emphasizes that Moga rechallenge should be encouraged as a first choice in relapsing patients.<\/jats:p>","DOI":"10.1093\/bjd\/ljae153","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T08:57:25Z","timestamp":1714035445000},"page":"143-144","source":"Crossref","is-referenced-by-count":9,"title":["Evolution of patients with S\u00e9zary syndrome after mogamulizumab discontinuation for any cause except progression: a multicentre retrospective study (Moga-stop Study)"],"prefix":"10.1093","volume":"191","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8129-5933","authenticated-orcid":false,"given":"Sofia","family":"Tzoumpa","sequence":"first","affiliation":[{"name":"Department of Dermatology, Henri-Mondor University Hospital , AP-HP, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5383-7096","authenticated-orcid":false,"given":"Saskia","family":"Ingen-Housz-Oro","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Henri-Mondor University Hospital , AP-HP, Cr\u00e9teil, France"},{"name":"Paris Est Cr\u00e9teil University , EpiDermE, Cr\u00e9teil, France"},{"name":"French Cutaneous Lymphomas Study Group (GFELC) , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ad\u00e8le","family":"de Masson","sequence":"additional","affiliation":[{"name":"French Cutaneous Lymphomas Study Group (GFELC) , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Pham-Ledard","sequence":"additional","affiliation":[{"name":"French Cutaneous Lymphomas Study Group (GFELC) , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarik","family":"El Aarbaoui","sequence":"additional","affiliation":[{"name":"Paris Est Cr\u00e9teil University , EpiDermE, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Dereure","sequence":"additional","affiliation":[{"name":"French Cutaneous Lymphomas Study Group (GFELC) , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00eblle","family":"Quereux","sequence":"additional","affiliation":[{"name":"French Cutaneous Lymphomas Study Group (GFELC) , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Faiz","sequence":"additional","affiliation":[{"name":"French Cutaneous Lymphomas Study Group (GFELC) , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"de Vicq de Cumptich","sequence":"additional","affiliation":[{"name":"French Cutaneous Lymphomas Study Group (GFELC) , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Ram-Wolff","sequence":"additional","affiliation":[{"name":"French Cutaneous Lymphomas Study Group (GFELC) , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00ebl","family":"Janela-Lapert","sequence":"additional","affiliation":[{"name":"French Cutaneous Lymphomas Study Group (GFELC) , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuella","family":"Guenova","sequence":"additional","affiliation":[{"name":"French Cutaneous Lymphomas Study Group (GFELC) , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coralie","family":"Lheure","sequence":"additional","affiliation":[{"name":"French Cutaneous Lymphomas Study Group (GFELC) , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Le Corre","sequence":"additional","affiliation":[{"name":"French Cutaneous Lymphomas Study Group (GFELC) , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri","family":"Adamski","sequence":"additional","affiliation":[{"name":"French Cutaneous Lymphomas Study Group (GFELC) , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9955-7172","authenticated-orcid":false,"given":"Ma\u00ebl","family":"Blanchard","sequence":"additional","affiliation":[{"name":"French Cutaneous Lymphomas Study Group (GFELC) , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Bonnet","sequence":"additional","affiliation":[{"name":"French Cutaneous Lymphomas Study Group (GFELC) , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Amatore","sequence":"additional","affiliation":[{"name":"French Cutaneous Lymphomas Study Group (GFELC) , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Grange","sequence":"additional","affiliation":[{"name":"French Cutaneous Lymphomas Study Group (GFELC) , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Troin","sequence":"additional","affiliation":[{"name":"French Cutaneous Lymphomas Study Group (GFELC) , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Bagot","sequence":"additional","affiliation":[{"name":"French Cutaneous Lymphomas Study Group (GFELC) , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6150-1229","authenticated-orcid":false,"given":"Marie","family":"Beylot-Barry","sequence":"additional","affiliation":[{"name":"French Cutaneous Lymphomas Study Group (GFELC) , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,25]]},"reference":[{"key":"2024062015120339300_ljae153-B1","doi-asserted-by":"crossref","first-page":"113343","DOI":"10.1016\/j.ejca.2023.113343","article-title":"EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary \u00adsyndrome\u00a0\u2013 update 2023","volume":"195","author":"Latzka","year":"2023","journal-title":"Eur J Cancer"},{"key":"2024062015120339300_ljae153-B2","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"key":"2024062015120339300_ljae153-B3","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1111\/jdv.19134","article-title":"Effectiveness of mogamulizumab in patients with Mycosis Fungoides or S\u00e9zary syndrome: a multicentre, retrospective, real-world French study","volume":"37","author":"Beylot-Barry","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024062015120339300_ljae153-B4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejca.2018.07.263","article-title":"Long-term complete remission induced by mogamulizumab in a severe S\u00e9zary patient, together with five different possible auto-immune manifestations","volume":"101","author":"Bonnet","year":"2018","journal-title":"Eur J Cancer"},{"key":"2024062015120339300_ljae153-B5","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/bjd.17320","article-title":"Association of autoimmunity and long-term complete remission in patients with S\u00e9zary syndrome treated with mogamulizumab","volume":"180","author":"Bonnet","year":"2019","journal-title":"Br J Dermatol"},{"key":"2024062015120339300_ljae153-B6","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.1182\/blood.2021014468","article-title":"Resistance to mogamulizumab is associated with loss of CCR4 in cutaneous T-cell lymphoma","volume":"139","author":"Beygi","year":"2022","journal-title":"Blood"},{"key":"2024062015120339300_ljae153-B7","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1182\/blood.2022016594","article-title":"Mechanisms of resistance to mogamulizumab","volume":"139","author":"Querfeld","year":"2022","journal-title":"Blood"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljae153\/57628656\/ljae153.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/191\/1\/143\/58289281\/ljae153.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/191\/1\/143\/58289281\/ljae153.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T15:26:54Z","timestamp":1718897214000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/191\/1\/143\/7657877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,25]]},"references-count":7,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,4,25]]},"published-print":{"date-parts":[[2024,6,20]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljae153","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2024,4,25]]}}}